All In Biotech

Drug Trial Radar · NCT01176240

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease

Last checked: Nov 20, 2026Latest source record: May 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

Jun 2010

Primary completion

Oct 2012

Study completion Nov 2012

Sponsor

Lead sponsor
Chelsea TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 5, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the effects of an investigational drug, Droxidopa, in participants with neurogenic orthostatic hypotension (NOH), associated with Parkinson's disease. Droxidopa is being studied to determine the effects on blood pressure changes upon standing up (orthostatic challenge). Symptoms and activity measurements, including patient reported falls, will be evaluated to determine the effectiveness of the study drug. Symptoms of NOH may include any of the following: * Dizziness, light-headedness, feeling faint or feeling like you may blackout * Problems with vision (blurring, seeing spots, tunnel vision, etc.) * Weakness * Fatigue * Trouble concentrating * Head \& neck discomfort (the coat hanger syndrome) * Difficulty standing for a short time or a long time * Trouble walking for a short time or a long time The study duration is a maximum of approximately 14 weeks including up to 2 weeks for screening, up to 2 weeks for proper dose finding, followed by an 8 week treatment period and a follow-up visit after 2 weeks. A sufficient number of patients will be screened to allow approximately 211 randomized patients. An extension study is also available to continue treatment if determined appropriate by the study doctor. This Study is NCT01132326 sponsored by Chelsea Therapeutics and is enrolling by invitation only.

Conditions

  • Orthostatic Hypotension
  • Parkinson's Disease

Interventions

  • DroxidopaDrug

    100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)Time frame: Baseline, Week 8
  2. 306B Efficacy: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1)Time frame: Baseline, Week1

Locations

60 sites in 1 country. Site status is shown where the registry gives one.

  • Neurology Neurodiagnostic Lab

    Alabaster, Alabama

  • Neurological Physicians of Arizona

    Gilbert, Arizona

  • Xenoscience

    Phoenix, Arizona

  • Barrow Neurology Clinic

    Phoenix, Arizona

  • Banner Health

    Sun City, Arizona

  • Center for Neurosciences

    Tucson, Arizona

  • Northwest Neuro Specialists P.L.L.C.

    Tucson, Arizona

  • Caring Clinical Research Incorporated

    Laguna Hills, California

  • Hoag Memorial Hospital, Presbyterian

    Newport Beach, California

  • Neurosearch - Pasadena

    Pasadena, California

  • Alliance Clinical Research, LLC

    Poway, California

  • Neurosearch, Inc.

    Reseda, California

  • Neurosearch II, Inc.

    Ventura, California

  • Neurology Consultants Medical Group

    Whittier, California

  • Associated Neurologist of Southern Connecticut, PC

    Fairfield, Connecticut

  • Hartford Hospital

    Hartford, Connecticut

  • Eastern Connecticut Neurology Specialists

    Manchester, Connecticut

  • Parkinson's Disease & Movement Disorder Disoder

    Boca Raton, Florida

  • Pharmax Research Clinic, LLC

    Miami, Florida

  • Neurology Associates of Ormond Beach

    Ormond Beach, Florida

  • Neurostudies Inc.

    Port Charlotte, Florida

  • Parkinson's Disease Treatment Center of Southwest Florida

    Port Charlotte, Florida

  • Lovelace Scientific Research

    Sarasota, Florida

  • Tampa General University of South Florida

    Tampa, Florida

  • Vero Neurology

    Vero Beach, Florida

  • Premiere Research Institute

    West Palm Beach, Florida

  • Emory University

    Atlanta, Georgia

  • Neurology Specialists of Decatur Research Center

    Decatur, Georgia

  • Prism Research Group

    Rome, Georgia

  • Alexian Brothers Hospital Network

    Elk Grove Village, Illinois

  • Precise Clinical Research

    Topeka, Kansas

  • North Oaks Health System

    Hammond, Louisiana

  • Harvard Vanguard Medical Associates

    Boston, Massachusetts

  • Detroit Clinical Research Center

    Novi, Michigan

  • Northern Michigan Neurology

    Traverse City, Michigan

  • Gulf Coast Neurology Center, PLLC

    Ocean Springs, Mississippi

  • University of Nevada School of Medicine

    Las Vegas, Nevada

  • Wellness and Research Center

    Belvidere, New Jersey

  • AdvanceMed Research

    Lawrenceville, New Jersey

  • Shore Neurology

    Toms River, New Jersey

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.